Fuda Cancer Hospital
Chondrosarcoma treatment cost in China typically relies on a combination of surgical intervention and advanced radiation. A major surgical procedure such as bone resection runs from $9,500 to $22,500, while specialized proton therapy runs from $36,500 to $47,500. Total expenses depend on the tumor stage, surgical complexity, and specific technology used. Patients often save 45% to 85% compared to US medical costs in cities like Guangzhou, Beijing, and Xiamen.
Typical Chondrosarcoma Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients benefit from centers specializing in minimally invasive technologies. Fuda Cancer Hospital offers specialized cryosurgery and NanoKnife therapies, treating over 30,000 international patients. For cases requiring complex multidisciplinary management, Xiamen Humanity Hospital provides comprehensive tertiary care with 47 clinical departments. Those needing high-precision radiation should consider specialists like Professor Liu Shi Xin. He is an expert in VMAT and SBRT at JCI-accredited facilities.
| China | Turkey | Austria | |
| Proton-beam therapy | from $36,500 | from $70,000 | from $80,000 |
| Proton therapy for prostate cancer | from $42,500 | from $30,000 | from $80,000 |
| Proton therapy for breast cancer | from $38,500 | from $30,000 | from $55,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Bone resection | from $9,500 | from $8,000 | from $25,000 |
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.
Chondrosarcoma treatment in China primarily focuses on wide surgical resection to ensure clear margins. Major centers utilize limb-sparing techniques, 3D-printed implants, and advanced particle therapy. For inoperable cases, specialists apply local ablation technologies like NanoKnife and cryosurgery to target tumors precisely.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in China. Fuda Cancer Hospital has treated over 30,000 international patients. Large-scale centers like Xiamen Humanity Hospital manage around 1,000,000 patients annually. This massive case volume allows Chinese surgeons to gain exceptional experience with rare subtypes over a short period.
Patient Consensus: Patients emphasize the need for expert pathology reviews because tumor grade determines the entire surgical plan. Choosing between limb-sparing surgery and amputation remains the most significant decision for those with extensive disease.
Advanced or high-grade chondrosarcomas in China are treated primarily through aggressive surgical resection using limb-salvage techniques. Surgeons aim for wide en-bloc removal to ensure negative margins. Integrated care models often combine surgery with high-energy particle therapy and specialized minimally invasive ablation for complex or late-stage cases.
Bookimed Expert Insight: While many facilities offer basic oncology, specialized centers like Fuda Cancer Hospital demonstrate higher capability for complex cases. They treat over 30,000 international patients using niche technologies like vascular interventional therapy and microwave hyperthermia. This high volume suggests that centers with localized ablative tools are often better equipped for patients with recurrent or hard-to-reach tumors.
Patient Consensus: Patients note it is critical to find a multidisciplinary sarcoma team because these tumors often resist standard chemotherapy. They emphasize that achieving clean surgical margins during the first procedure is the most important factor for long-term success.
China is home to prominent hospitals specializing in chondrosarcoma treatment. Institutions like Fuda Cancer Hospital and Xiamen Humanity Hospital lead in surgical and interventional oncology. These centers offer advanced orthopedic oncology surgery. They use 3D-printed reconstructions and targeted ablation therapies for complex bone malignancies.
Bookimed Expert Insight: Patient volume often signals where the highest level of specialized expertise lies. While Fuda Cancer Hospital serves over 30,000 international patients, Xiamen Humanity Hospital treats around 1,000,000 patients annually. Large-scale institutions like these often house the most experienced surgeons. They are more likely to successfully manage rare cases like chondrosarcoma.
Patient Consensus: Patients note that finding a dedicated orthopedic oncology team is more important than hospital prestige. They emphasize that regular pathology reviews are vital. These can change the tumor grade and completely alter treatment plans.
In China, the five-year survival rate for chondrosarcoma patients ranges between 75% and 80%. Long-term outcomes for ten years remain high at approximately 60%. These metrics represent the highest survival outcomes among all primary malignant bone tumors managed within the country.
Bookimed Expert Insight: Patients should prioritize tertiary facilities like Xiamen Humanity Hospital or JCI-accredited Fuda Cancer Hospital. Large centers in China manage massive volumes. Xiamen Humanity Hospital alone treats 1,000,000 patients annually. This high frequency with complex cases often leads to better preservation of limb function.
Patient Consensus: Patients emphasize that low-grade tumors feel like a chronic manageable condition. They note that getting a second pathology opinion is vital because initial biopsies are often incomplete.
Traditional Chinese Medicine (TCM) serves strictly as supportive care for chondrosarcoma. It does not cure the tumor. Surgical resection remains the primary medical standard. Chinese oncology centers integrate acupuncture and herbal tonics to manage pain, nausea, and immune stability during recovery.
Bookimed Expert Insight: Patients Choosing Chinese centers like Fuda Cancer Hospital often prioritize its JCI-accredited integration of minimally invasive techniques. While many seek TCM, the real value lies in combining it with advanced cryosurgery or NanoKnife. This approach targets tumors while using traditional methods only to boost post-operative recovery speed.
Patient Consensus: Patients emphasize that TCM should never delay surgery. They note it is most helpful for regaining appetite and managing stress during the recovery phase.